Pooled-analysis of prospective observational studies evaluated the efficacy and safety of bevacizumab(BEV) and paclitaxel(PTX) as the first-line chemotherapy for HER2-negative metastatic breast cancer(MBC).
Phase 4
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000047290
- Lead Sponsor
- Japan Breast Cancer Research Group
- Brief Summary
The median OS was 21.4 M 7 independent prognostic factors for OS were identified (tumor subtype, age, ECOG PS, DFI, liver metastasis, number of metastatic organs, prior anthracycline or taxane treatment).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 2474
Inclusion Criteria
Not provided
Exclusion Criteria
Key exclusion criteria in each study (B-SHARE,ML21165,AVAREG,AVANTI)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method Progression free survival Objective response rate Time to treatment failure OS and PFS stratified by the prognostic factor index safety